These drugs competitively inhibited the ATP binding domain of EGFR, effectively blocking the abnormal signal transduction, and so have been used in the first-line treatment of EGFR-mutated NSCLC [48]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.